Product Description
Adapalene is used to treat acne. Adapalene is in a class of medications called retinoid-like compounds. It works by stopping pimples from forming under the surface of the skin.
Mechanisms of Action: RAR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Acne Vulgaris | Acne Vulgaris
Known Adverse Events: Erythema | Dermatitis | Dermatitis, Contact
Company: Galderma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, United States, Unknown Location
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Acne Vulgaris
Phase 1: Cholangitis, Sclerosing|Intestinal Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| IRB00089304 | P1 |
Recruiting |
Acne Vulgaris |
2025-05-01 |
|
| ABCG-2407 | P1 |
Completed |
Acne Vulgaris |
2024-09-03 |
|
| CTR20181049 | P3 |
Active, not recruiting |
Acne Vulgaris |
2020-04-07 |
|
| 2006-7041-83/hah | P1 |
Not yet recruiting |
Intestinal Diseases|Cholangitis, Sclerosing |
2017-02-13 |